> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AuroLife Pharma Form 483 Issued After Inspection
- URL: https://www.fdaweb.com/aurolife-pharma-form-483-issued-after-inspection/
- Published: 2020-06-04T12:00:00.000Z
- Updated: 2026-09-14T16:17:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146936

India-based Aurobindo Pharma says that an FDA inspection earlier this year at its oral solid manufacturing facility in Dayton, NH, AuroLife Pharma, resulted in a Form 483 citing nine GMP observations. The agency notified the company that the 1/13 to 2/12 inspection was classified as “official action indicated,” which the company says will have no material impact on its existing revenues or drug supplies from its U.S. business. Almost 50% of the company’s revenue comes from the U.S. market, but the NJ facility accounts for just 2% of total revenue.